Ocular Therapeutix (OCUL) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 213.9% versus a loss of 54.5%. Over five years, SLN leads with a -10.0% price change compared with -14.8% for OCUL. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($1.23 billion vs $1.23 billion), about 1.0 times the size, while Ocular Therapeutix is growing revenue faster (-18.5% vs -98.7%).
Ocular Therapeutix converts more of its revenue into profit, with a net margin of -511.9% versus -15851.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | SLN |
|---|---|---|
| Share price | $5.57 | $19.81 |
| Market cap | $1.23B | $1.23B |
| 1-day change | -4.95% | 0.00% |
| YTD return | -54.12% | +225.82% |
| 1-year return | -54.49% | +213.95% |
| 5-year return | -14.83% | -9.95% |
| EPS (TTM) | $-1.44 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $51.95M | $559.00K |
| Revenue growth (YoY) | -18.47% | -98.71% |
| Net income (latest FY) | $-265.94M | $-88.61M |
| Gross margin | 87.35% | 61.54% |
| Operating margin | -519.75% | -16292.84% |
| Net margin | -511.90% | -15851.88% |
| 52-week high | $16.44 | $19.87 |
| 52-week low | $5.54 | $4.19 |
| Distance from 52-week high | -66.12% | -0.28% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +361.94% | -0.30% |
| Average volume | 3.03M | 2.41M |
| Shares outstanding | 220.02M | 62.20M |
| Employees | 325 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed OCUL by 268.4 percentage points over the past year.
- Ocular Therapeutix is more profitable, keeping -511.9 cents of every revenue dollar as net income versus -15851.9 cents for Silence Therapeutics Plc American Depository Share.
- Ocular Therapeutix grew revenue faster in its latest fiscal year (-18.47% vs -98.71%).
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
OCUL vs SLN FAQ
Which is bigger, Ocular Therapeutix or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $1.23B compared with $1.23B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, OCUL or SLN?
SLN returned +213.95% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.